Findings

What do systematic reviews say?

188 questions · 190 findings · 13 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 50 · 26.3%GRADE not reported 0 · 0%Very low 48 · 25.3%Low 52 · 27.4%Moderate 30 · 15.8%High 10 · 5.3%

Benzoyl peroxide vs salicylic acid

Withdrawals due to adverse events · participants with acne

1 finding from 1 review

Topical benzoyl peroxide for acne 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
Very low

Benzoyl peroxide vs salicylic acid

Adverse effect/event: 2. Adverse effects ‐ any ‐ medium‐termonly · participants with acne

It is very uncertain whether benzoyl peroxide changes total number of participants with any adverse events (medium‐term… compared with salicylic acid (very low certainty).

1 finding from 1 review

Topical benzoyl peroxide for acne 2020 · Cochrane Headline outcomes only
RR 4.77 [0.24, 93.67]
1 study · 41 participants
Very low

Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Radiologic relapse · people with surgically‐induced remission in Crohn's disease

It is very uncertain whether azathioprine or 6‐mercaptopurine changes radiologic relapse compared with 5‐aminosalicylic acid (very low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.92 [0.66, 1.28]
1 study · 35 participants
Very low

Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Surgical relapse · people with surgically‐induced remission in Crohn's disease

It is very uncertain whether azathioprine or 6‐mercaptopurine changes surgical relapse compared with 5‐aminosalicylic acid (very low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.81 [0.5, 1.29]
1 study · 142 participants
Very low

Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Adverse events · people with surgically‐induced remission in Crohn's disease

Azathioprine or 6‐mercaptopurine showed no clear difference in adverse events compared with 5‐aminosalicylic acid (low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.89 [0.74, 1.07]
4 studies · 346 participants
Low

Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Serious adverse events · people with surgically‐induced remission in Crohn's disease

It is very uncertain whether azathioprine or 6‐mercaptopurine changes serious adverse events compared with 5‐aminosalicylic acid (very low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 3.39 [1.26, 9.13]
3 studies · 311 participants
Very low

Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease

Azathioprine or 6‐mercaptopurine may leads to higher withdrawal due to adverse events compared with 5‐aminosalicylic acid (low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 2.21 [1.28, 3.81]
4 studies · 425 participants
Low

Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Clinical relapse · people with surgically‐induced remission in Crohn's disease

Azathioprine or 6‐mercaptopurine showed no clear difference in clinical relapse compared with 5‐aminosalicylic acid (low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.05 [0.89, 1.24]
4 studies · 347 participants
Low

Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Endoscopic relapse · people with surgically‐induced remission in Crohn's disease

It is very uncertain whether azathioprine or 6‐mercaptopurine changes endoscopic relapse compared with 5‐aminosalicylic acid (very low certainty).

1 finding from 1 review

Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 0.78 [0.52, 1.17]
1 study · 35 participants
Very low

Methotrexate vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Clinical remission · patients with induction of remission in ulcerative colitis

It is very uncertain whether methotrexate changes proportion of patients achieved clinical remission compared with 5‐aminosalicylic acid (5‐ASA) (very low certainty).

1 finding from 1 review

Methotrexate for induction of remission in ulcerative colitis 2014 · Cochrane Headline outcomes only
RR 2.33 [0.66, 3.64]
1 study · 20 participants
Very low

Oral 5‐ASA vs placebo

Failure to induce global or clinical remission · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA leads to lower failure to induce complete global or clinical remission compared with placebo (high certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.86 [0.82, 0.89]
11 studies · 2387 participants
High

Oral 5‐ASA vs SASP

Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis

The review found no eligible studies for this question.

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral 5‐ASA vs SASP

Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis

The review found no eligible studies for this question.

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral 5‐ASA vs SASP

Adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA probably leads to lower adverse events compared with SASP (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.48 [0.36, 0.63]
12 studies · 909 participants
Moderate

Oral 5‐ASA vs SASP

Serious adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA showed no clear difference in serious adverse events compared with SASP (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.36 [0.28, 6.52]
2 studies · 107 participants
Low

Oral 5‐ASA vs SASP

Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis

Oral 5‐ASA probably leads to lower withdrawal due to adverse events compared with SASP (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.4 [0.24, 0.68]
10 studies · 640 participants
Moderate

Once daily dosing vs conventional dosing

Failure to induce global or clinical remission · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in failure to induce global or clinical remission compared with conventional dosing (high certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.99 [0.93, 1.06]
5 studies · 1761 participants
High

Once daily dosing vs conventional dosing

Failure to induce global or clinical improvement · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in failure to induce global or clinical improvement compared with conventional dosing (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.74 [0.49, 1.1]
3 studies · 564 participants
Moderate

Once daily dosing vs conventional dosing

Failure to induce endoscopic remission · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in failure to induce endoscopic remission compared with conventional dosing (high certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.02 [0.98, 1.07]
1 study · 817 participants
High

Once daily dosing vs conventional dosing

Failure to adhere to medication regimen · Patients with active mild to moderate ulcerative colitis

Once daily dosing showed no clear difference in failure to adhere to medication regimen compared with conventional dosing (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.36 [0.64, 2.86]
2 studies · 358 participants
Low